PsyBrain 脑心前沿 / 科研分析：认知神经科学前沿的结构化精读 / Y · 脑疾病与临床 / Y056 · PNAS非侵入治疗AD新线索：40Hz听觉刺激的长期效应

Y056 PNAS | 非侵入治疗AD新线索：40Hz听觉刺激的长期效应（老年猴研究）

来源：公众号 PSY-Brain_Frontier ｜发布：2026-01-14 ｜原文链接

PsyBrain 脑心前沿 | 公众号 PSY-Brain_Frontier

一键关注，点亮星标 ⭐️

第一时间接收每日前沿资讯

认知神经科学前沿文献分享

基本信息：

Title: Long-term effects of forty-hertz auditory stimulation as a treatment of Alzheimer’s disease: Insights from an aged monkey model study

发表时间：2026.1.5

Journal: PNAS

影响因子：9.1

获取原文：

*添加小助手:*PSY-Brain-Frontier即可获取PDF版本
点击页面底部“阅读原文”即可跳转论文原网页

引言

阿尔茨海默病（Alzheimer’s disease, AD）最让人无力的地方，不是“记不住”，而是它会把学习与记忆这些最核心的能力一点点磨掉。过去几年，靶向淀粉样蛋白β（amyloid-beta, Aβ）的一些单克隆抗体药物进入临床并获批，但整体疗效多为“减速”而非“逆转”，同时还伴随脑水肿、出血等安全性问题，让“更温和、更可长期使用”的方案显得格外迫切。

于是，一个看起来有点“反直觉”的思路逐渐走红：不靠药物，而用40 Hz的节律性刺激去“带节奏”大脑。40 Hz对应脑电的γ振荡（gamma oscillations），而γ振荡在AD患者与模型动物中往往减弱。啮齿动物研究提示，40 Hz的光/声刺激可能降低Aβ负担、改善相关病理，并可能通过类淋巴系统（glymphatic system）促进代谢废物清除。

但问题也很现实：小鼠并不会自然发生AD，模型多依赖家族性突变；更关键的是，啮齿类与人类在脑结构与脑脊液循环等方面差异明显，导致“鼠有效、人无效”的翻译失败屡见不鲜。

因此，在真正走向临床前，必须在更接近人类的非人灵长类（nonhuman primates）中做关键验证。本研究抓住罕见机会，直接在26–31岁的老年恒河猴（rhesus monkeys）上开展40 Hz听觉刺激，并以脑脊液（cerebrospinal fluid, CSF）中的Aβ与Tau作为“临床同款”生物标志物读数，去回答一个核心问题：40 Hz声音刺激到底能否、以及能在多长时间尺度上调动老年灵长类大脑的Aβ/Tau代谢？

实验设计与方法逻辑

作者将9只老年恒河猴随机分为三组：40 Hz听觉刺激组、随机节律刺激组与无声音处理对照组，通过“同样操作、不同刺激”把声音节律本身的特异效应从操作与环境因素中剥离；每轮刺激为连续7天、每天1小时，关键时间点多次腰穿采集CSF，用超敏单分子阵列（single molecule array, Simoa）检测Aβ42、Aβ40、总Tau（t-Tau）与磷酸化Tau（p-Tau181），并在部分个体终点进行免疫组化（6E10标记Aβ斑块、AT180标记磷酸化Tau）验证脑内病理基础，从而把“体液变化—时间维持—组织证据”串成闭环。

核心发现

40 Hz听觉刺激可快速提升CSF Aβ：连续7天、每天1小时的40 Hz声音刺激，使脑脊液Aβ42与Aβ40升至约2倍；随机节律或无声音对照均无此变化。

效应具有长时程“尾效应”：停止刺激后，CSF Aβ升高仍可持续5周以上（至49天）。

Tau通路未见显著响应：CSF总Tau（t-Tau）与磷酸化Tau（p-Tau181）在各组、各时间点均无显著改变。

组织学解释一致：老年猴脑内Aβ斑块普遍存在，而磷酸化Tau沉积缺失或极轻，与体液结果相吻合。

归纳总结和点评

这项工作最硬核的价值在于“把40 Hz从小鼠推到灵长类”，为“非侵入、可长期管理”的AD干预提供了难得的灵长类证据与可检验的机制假说，属于向临床可转化迈出的关键一步。

核心图表

Fig. 1. Experimental design and the effects of 40-Hz [Group (a)], random [Group (b)] or no auditory stimulation [Group (c)] on CSF Aβ42 and Aβ40 concentrations in aged monkeys.

图10

Fig. 2. Long-term effects of 40-Hz stimulation on CSF Aβ42 and Aβ40 levels of aged monkeys.

图11

图12

Fig. 3. The effects of 40-Hz [Group (a)], random [Group (b)] or no [Group (c)] auditory stimulation on CSF concentrations of t-Tau and p-Tau 181 in aged monkeys.

图13

Fig. 4. Representative images of Aβ pathology stained by 6E10 in TC of four aged monkeys.

图14

Fig. 5. Representative images of Tau pathology stained by AT180 in TC of four aged monkeys.

图15

Abstract

Based mainly on rodents studies, forty-hertz (40-Hz) physical stimulation has been regarded as a potential noninvasive treatment for Alzheimer’s disease (AD). Considering the brain differences between rodents and humans, the effects of 40-Hz physical stimulation need to be further validated using nonhuman primates before its clinical application. Here, we took advantage of a rare opportunity to expose nine aged rhesus monkeys (26 to 31 y old) to 40-Hz auditory stimulation. Given the strong correlation between cerebrospinal fluid (CSF) Aβ and Tau concentrations and corresponding AD pathology in brain parenchyma in clinical practice, we investigated the effects of 40-Hz stimulation on AD pathology by monitoring changes in CSF Aβ and Tau concentrations. Our results revealed that 7 consecutive days of 40-Hz auditory stimulation triggered a rapid and significant increase of Aβ levels by more than 200%, but no effect on Tau levels in the CSF. Additionally, we observed that the elevation of CSF Aβ levels persisted for more than 5 wk after cessation, which had not been reported in any previous studies. After this, a pathological examination of the temporal cortices of 4 of the experimental monkeys was carried out and the data demonstrated that all of them had prevalent extracellular Aβ senile plaque pathology, whereas Tau pathology was negative or very weak. These results provide a good explanation for the differences between the CSF Aβ and Tau protein levels. Together, these first-time results from monkeys suggest that 40-Hz auditory stimulation has strong potential of a noninvasive AD treatment method.

前沿交流 | 欢迎加入认知神经科学前沿交流群！

⭐️[加群链接]

图16